Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. FORA
FORA logo

FORA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.100
Open
2.085
VWAP
2.08
Vol
33.01K
Mkt Cap
64.63M
Low
2.060
Amount
68.66K
EV/EBITDA(TTM)
--
Total Shares
31.07M
EV
36.72M
EV/OCF(TTM)
25.97
P/S(TTM)
2.32
Forian Inc. is a healthtech company. The Company is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers. The Company has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. The Company’s offerings include commercial, Real World Evidence (RWE) and market access solutions and proprietary data-driven insights to optimize the operational, clinical and financial performance of its customers. Its solutions include CHRONOS, Chartis, RWE and Kyber Data Science. CHRONOS, combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model.
Show More

Events Timeline

(ET)
2025-08-25
13:29:16
Forian reveals it has received an unsolicited proposal to go private at $2.10 per share.
select
link
2024-11-13 (ET)
2024-11-13
15:06:39
Forian reports Q3 EPS (1c), consensus (3c)
select
2024-11-01 (ET)
2024-11-01
09:02:27
Forian acquires Kyber Data Science from TD Cowen, terms not disclosed
select

News

Businesswire
9.5
03-03Businesswire
VerticalScope Reports Strong Q4 2025 Financial Results with AI Growth Potential
  • Strong Financial Performance: VerticalScope reported $15.4 million in revenue for Q4 2025, a 22% year-over-year decline, yet achieved an Adjusted EBITDA of $6.9 million, demonstrating resilience and profitability amid challenges.
  • Significant User Growth: The company's direct user base grew by 21% year-over-year, which not only strengthens its community-driven business model but also lays a solid foundation for future revenue growth, particularly with double-digit growth in e-commerce.
  • AI Technology Driving Innovation: The newly launched AudienceEngine technology quickly reached a $1.4 million annualized EBITDA run rate in January, despite limited contributions during its Q4 beta phase, showcasing AI's immense potential in enhancing user engagement and optimizing revenue.
  • Enhanced Liquidity: VerticalScope exited 2025 with $72 million in total available liquidity, ensuring financial flexibility for future investments in AI initiatives and strategic acquisitions, further propelling its growth strategy.
Businesswire
9.5
02-19Businesswire
VerticalScope Announces 2025 Financial Results Release Schedule
  • Financial Results Schedule: VerticalScope plans to release its fourth quarter and full year 2025 financial results after market close on March 3, 2026, showcasing the company's operational achievements in high-consumer spending online community platforms.
  • Conference Call Details: The company will host a conference call and webcast on March 4, 2026, at 8:00 a.m. ET to discuss the financial results, which is expected to attract significant attention from investors and analysts.
  • Online Community Platform: Since its founding in 1999, VerticalScope has built over 1,200 online communities with approximately 90 million monthly active users, demonstrating its strong influence and market penetration in the digital platform space.
  • Forward-Looking Statements: The company notes that the timing of the financial results release is based on various assumptions and is subject to risks and uncertainties, with actual results potentially differing significantly from expectations, emphasizing transparency and accountability to investors.
NASDAQ.COM
3.0
2025-11-14NASDAQ.COM
Earnings Report for November 14, 2025: QUBT, HIVE, VENU, NXXT, MDV, DFLI, FORA, BEEM, TOMZ, BNZI Released After Market Hours
  • Earnings Reports Overview: Several companies, including Quantum Computing Inc. (QUBT), HIVE Digital Technologies Ltd (HIVE), and Venu Holding Corporation (VENU), are set to report earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.

  • Performance Expectations: QUBT is expected to see a 16.67% increase in earnings per share (EPS) compared to last year, while HIVE anticipates an 83.33% increase. In contrast, companies like Forian Inc. (FORA) and Beam Global (BEEM) are projected to experience significant decreases in EPS.

  • Price to Earnings Ratios: The Price to Earnings (P/E) ratios for these companies vary widely, with QUBT at -55.72 and HIVE at -61.00, indicating differing growth expectations compared to their industry averages.

  • Analyst Consensus and Surprises: Many companies, such as Banzai International, Inc. (BNZI) and TOMI Environmental Solutions, Inc. (TOMZ), have faced challenges in meeting analyst expectations, with some reporting significant negative surprises in previous quarters.

SeekingAlpha
7.0
2025-11-14SeekingAlpha
Forian sets 2025 revenue growth target of 39%-49% fueled by Kyber integration in health data analytics expansion.
  • Strong Revenue Growth: Forian Inc. reported a 66% year-over-year increase in Q3 2025 revenue, reaching $7.76 million, largely driven by the acquisition of Kyber Data Science and growth in health economics and outcomes research.

  • Optimistic Outlook: Management reaffirmed its 2025 revenue guidance of $28 million to $30 million, expecting to finish at the high end of this range, while also highlighting improved operating leverage and ongoing investments in data innovation.

  • Integration of Kyber Data Science: The acquisition has enhanced Forian's analytical capabilities, particularly in financial markets, allowing clients to gain predictive insights and improve treatment outcomes.

  • Lack of Analyst Engagement: The earnings call featured no analyst questions, indicating a lack of public scrutiny, but management maintained a confident tone regarding the company's performance and future prospects.

Newsfilter
9.5
2025-08-13Newsfilter
Forian Inc. (FORA) Q2 2025 Earnings Call Transcript
  • Earnings Conference Call Overview: Forian Inc. held its Q2 2025 earnings conference call on August 13, 2025, featuring CEO Max Wygod and CFO Michael Vesey discussing the company's financial results and future outlook.

  • Forward-Looking Statements Warning: The management emphasized that their remarks may include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ from projections made during the call.

NASDAQ.COM
9.5
2025-05-08NASDAQ.COM
PDF Solutions (PDFS) Q1 Earnings Beat Estimates
  • Earnings Performance: PDF Solutions reported quarterly earnings of $0.21 per share, exceeding estimates and showing growth from $0.15 per share a year ago, but missed revenue expectations with $47.78 million compared to the consensus estimate.

  • Market Outlook: The company's stock has underperformed this year, down 29.5%, and currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future, while industry trends may impact its performance.

Wall Street analysts forecast FORA stock price to rise
1 Analyst Rating
Wall Street analysts forecast FORA stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
2.10
Averages
2.10
High
2.10
Current: 0.000
sliders
Low
2.10
Averages
2.10
High
2.10
Roth Capital
Buy -> Neutral
downgrade
$5
AI Analysis
2025-11-17
Reason
Roth Capital
Price Target
$5
AI Analysis
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5.
Roth Capital
Richard Baldry
Buy -> Neutral
downgrade
$5
2025-11-17
Reason
Roth Capital
Richard Baldry
Price Target
$5
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital analyst Richard Baldry downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5. The company reported good Q3 results but the shares offer little upside given the majority of shareholders have chosen to take Forian private at $2.10 per share, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FORA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Forian Inc (FORA.O) is -42.40, compared to its 5-year average forward P/E of -12.90. For a more detailed relative valuation and DCF analysis to assess Forian Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.90
Current PE
-42.40
Overvalued PE
10.05
Undervalued PE
-35.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
67.81
Current EV/EBITDA
33.13
Overvalued EV/EBITDA
175.91
Undervalued EV/EBITDA
-40.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.24
Current PS
2.10
Overvalued PS
5.32
Undervalued PS
1.17

Financials

AI Analysis
Annual
Quarterly

Whales Holding FORA

S
Staley Capital Advisers, Inc.
Holding
FORA
-1.48%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Forian Inc (FORA) stock price today?

The current price of FORA is 2.08 USD — it has decreased -0.48

What is Forian Inc (FORA)'s business?

Forian Inc. is a healthtech company. The Company is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers. The Company has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. The Company’s offerings include commercial, Real World Evidence (RWE) and market access solutions and proprietary data-driven insights to optimize the operational, clinical and financial performance of its customers. Its solutions include CHRONOS, Chartis, RWE and Kyber Data Science. CHRONOS, combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model.

What is the price predicton of FORA Stock?

Wall Street analysts forecast FORA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FORA is2.10 USD with a low forecast of 2.10 USD and a high forecast of 2.10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Forian Inc (FORA)'s revenue for the last quarter?

Forian Inc revenue for the last quarter amounts to 7.76M USD, increased 65.64

What is Forian Inc (FORA)'s earnings per share (EPS) for the last quarter?

Forian Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00

How many employees does Forian Inc (FORA). have?

Forian Inc (FORA) has 1 emplpoyees as of March 11 2026.

What is Forian Inc (FORA) market cap?

Today FORA has the market capitalization of 64.63M USD.